Key result
Aspirin provides a modest 20% relative risk reduction for recurrent stroke or TIA, but further controlled trials are needed to justify combining different antiplatelet drugs.
Why the study?
How should antiplatelet drugs be selected and combined to prevent recurrent stroke or major vascular events in patients with prior TIA or stroke?
Population
Patients who have undergone TIA or stroke
Design
Review
Authors
Loading...
Aspirin monotherapy remains appropriate for secondary prevention; leaves open justification for dual regimens pending new trials.
How should antiplatelet drugs be selected and combined to prevent recurrent stroke or major vascular events in patients with prior TIA or stroke?
This review outlines the standard antiplatelet options for secondary stroke prevention and highlights the need for further trials to validate the efficacy of combining different antiplatelet agents.
Natan M. Bornstein (2001) conducted a review in TIA or stroke. Antiplatelet drugs (aspirin, clopidogrel, dipyridamole) was evaluated. Aspirin provides a modest 20% relative risk reduction for recurrent stroke or TIA, but further controlled trials are needed to justify combining different antiplatelet drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: